Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCG-2025 low-risk childhood B-cell ALL protocol with blinatumomab-based intensification
ChiCTR2500098655Phase 3Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: 3-year event-free survival rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on ChiCTR2500098655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098655.